TY - JOUR
T1 - Targets of neuroprotection in glaucoma
AU - He, Shaoqing
AU - Stankowska, Dorota L.
AU - Ellis, Dorette Z.
AU - Krishnamoorthy, Raghu R.
AU - Yorio, Thomas
N1 - Funding Information:
This article was partially supported by the Department of Defence (W81XH-10-2-0003) to T.Y., the NEI grant (1R01EY019952) to R.R.K. and a grant from 2016 Fight for Sight Grant-in-Aid to D.S.
Publisher Copyright:
© Copyright 2018, Mary Ann Liebert, Inc.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Progressive neurodegeneration of the optic nerve and the loss of retinal ganglion cells is a hallmark of glaucoma, the leading cause of irreversible blindness worldwide, with primary open-angle glaucoma (POAG) being the most frequent form of glaucoma in the Western world. While some genetic mutations have been identified for some glaucomas, those associated with POAG are limited and for most POAG patients, the etiology is still unclear. Unfortunately, treatment of this neurodegenerative disease and other retinal degenerative diseases is lacking. For POAG, most of the treatments focus on reducing aqueous humor formation, enhancing uveoscleral or conventional outflow, or lowering intraocular pressure through surgical means. These efforts, in some cases, do not always lead to a prevention of vision loss and therefore other strategies are needed to reduce or reverse the progressive neurodegeneration. In this review, we will highlight some of the ocular pharmacological approaches that are being tested to reduce neurodegeneration and provide some form of neuroprotection.
AB - Progressive neurodegeneration of the optic nerve and the loss of retinal ganglion cells is a hallmark of glaucoma, the leading cause of irreversible blindness worldwide, with primary open-angle glaucoma (POAG) being the most frequent form of glaucoma in the Western world. While some genetic mutations have been identified for some glaucomas, those associated with POAG are limited and for most POAG patients, the etiology is still unclear. Unfortunately, treatment of this neurodegenerative disease and other retinal degenerative diseases is lacking. For POAG, most of the treatments focus on reducing aqueous humor formation, enhancing uveoscleral or conventional outflow, or lowering intraocular pressure through surgical means. These efforts, in some cases, do not always lead to a prevention of vision loss and therefore other strategies are needed to reduce or reverse the progressive neurodegeneration. In this review, we will highlight some of the ocular pharmacological approaches that are being tested to reduce neurodegeneration and provide some form of neuroprotection.
KW - drug targets
KW - glaucoma
KW - neuroprotection
UR - http://www.scopus.com/inward/record.url?scp=85041904060&partnerID=8YFLogxK
U2 - 10.1089/jop.2017.0041
DO - 10.1089/jop.2017.0041
M3 - Article
C2 - 28820649
AN - SCOPUS:85041904060
SN - 1080-7683
VL - 34
SP - 85
EP - 106
JO - Journal of Ocular Pharmacology and Therapeutics
JF - Journal of Ocular Pharmacology and Therapeutics
IS - 1-2
ER -